Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECAR01 in Relapsed/Refractory B-Cell Malignancies
NCT06961669Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Apr 2025
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ECAR01 in multiple myeloma (MM), B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Adverse events at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
ECAR01
03
Conditions
multiple myeloma (MM)B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT06961669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961669.